EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
CAMBRIDGE, Mass., Oct. 26, 2017 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, November 2, 2017 at 9:00 a.m. ET to discuss financial results for the third quarter of 2017. Genocea management will also provide an update on the Company's recent progress and upcoming milestones.
Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 95267931. To join the live webcast, please visit the investor relations section of the Genocea website at http://ir.genocea.com.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.
About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines and exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea is exploring strategic alternatives for GEN-003, its Phase 3-ready immunotherapy candidate for the treatment of genital herpes. For more information, please visit www.genocea.com.
| For media: | For investors: |
| Jennifer LaVin | Jonathan Poole |
| O: 617-715-6687 | O: 617-876-8191 |
| [email protected] | [email protected] |
